M Franchini

Summary

Affiliation: University of Parma
Country: Italy

Publications

  1. ncbi Acquired hemophilia A
    Massimo Franchini
    Department of Pathology and Laboratory Medicine, Immunohematology and Transfusion Center, University Hospital of Parma, Parma, Italy
    Adv Clin Chem 54:71-80. 2011
  2. pmc Past, present and future of hemophilia: a narrative review
    Massimo Franchini
    Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Milan, Italy
    Orphanet J Rare Dis 7:24. 2012
  3. ncbi Pathogenesis, laboratory, and clinical characteristics of Helicobacter pylori-associated immune thrombocytopenic purpura
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Italy
    Adv Clin Chem 52:131-44. 2010
  4. doi [Acquired hemophilia: update on diagnosis and treatment]
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria, Parma
    Recenti Prog Med 102:286-9. 2011
  5. doi Factor V Leiden and hemophilia
    Massimo Franchini
    Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Parma, Italy
    Thromb Res 125:119-23. 2010
  6. doi Glanzmann thrombasthenia: an update
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Clin Chim Acta 411:1-6. 2010
  7. doi Factor V Leiden in women: a thrombotic risk factor or an evolutionary advantage?
    Massimo Franchini
    Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Parma, Italy
    Semin Thromb Hemost 37:275-9. 2011
  8. doi Multiple gene interaction and modulation of hemostatic balance
    Massimo Franchini
    Department of Pathology and Laboratory Medicine, Immunohematology and Transfusion Center, University Hospital of Parma, Parma, Italy
    Clin Chem Lab Med 47:1455-60. 2009
  9. pmc Evaluation of cryopreserved donor skin viability: the experience of the regional tissue bank of Verona
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Blood Transfus 7:100-5. 2009
  10. doi The use of desmopressin in mild hemophilia A
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Blood Coagul Fibrinolysis 21:615-9. 2010

Collaborators

Detail Information

Publications93

  1. ncbi Acquired hemophilia A
    Massimo Franchini
    Department of Pathology and Laboratory Medicine, Immunohematology and Transfusion Center, University Hospital of Parma, Parma, Italy
    Adv Clin Chem 54:71-80. 2011
    ..In this review the actual knowledge on diagnostic and therapeutic aspects of this disease will be summarized...
  2. pmc Past, present and future of hemophilia: a narrative review
    Massimo Franchini
    Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Milan, Italy
    Orphanet J Rare Dis 7:24. 2012
    ..Finally, intensive research is devoted to gene transfer therapy, the only way to ultimately obtain cure in hemophilia...
  3. ncbi Pathogenesis, laboratory, and clinical characteristics of Helicobacter pylori-associated immune thrombocytopenic purpura
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Italy
    Adv Clin Chem 52:131-44. 2010
    ..The aim of this review is to analyze the current knowledge on the pathogenic, diagnostic, clinical, and therapeutic characteristics of H. pylori-associated ITP...
  4. doi [Acquired hemophilia: update on diagnosis and treatment]
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria, Parma
    Recenti Prog Med 102:286-9. 2011
    ..In this paper, current knowledgs on diagnostic and therapeutic aspects of this disease are summarized...
  5. doi Factor V Leiden and hemophilia
    Massimo Franchini
    Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Parma, Italy
    Thromb Res 125:119-23. 2010
    ....
  6. doi Glanzmann thrombasthenia: an update
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Clin Chim Acta 411:1-6. 2010
    ..In this review we discuss the main characteristics of GT, focusing on molecular defects, diagnostic evaluation and treatment strategies...
  7. doi Factor V Leiden in women: a thrombotic risk factor or an evolutionary advantage?
    Massimo Franchini
    Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Parma, Italy
    Semin Thromb Hemost 37:275-9. 2011
    ..The results of the most important meta-analyses on the relationship between inherited (factor V Leiden) and acquired thrombophilia in women are analyzed in this review, along with the possible evolutionary role of this mutation...
  8. doi Multiple gene interaction and modulation of hemostatic balance
    Massimo Franchini
    Department of Pathology and Laboratory Medicine, Immunohematology and Transfusion Center, University Hospital of Parma, Parma, Italy
    Clin Chem Lab Med 47:1455-60. 2009
    ..The role of genetic factors on the modulation of the phenotypic expression of coagulation disorders will be addressed in this review, with particular emphasis on the underlying pathogenic mechanisms and clinical implications...
  9. pmc Evaluation of cryopreserved donor skin viability: the experience of the regional tissue bank of Verona
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Blood Transfus 7:100-5. 2009
    ..In this study we evaluated the cellular viability of cryopreserved skin at the regional tissue bank of Verona (Italy)...
  10. doi The use of desmopressin in mild hemophilia A
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Blood Coagul Fibrinolysis 21:615-9. 2010
    ..In this paper, we summarize the current knowledge on the mechanisms of action as well as its biological effects in patients with mild hemophilia A. The results of the most important clinical trials in this setting are also reviewed...
  11. doi Low-density lipoprotein receptor-related protein 1: new functions for an old molecule
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Clin Chem Lab Med 49:967-70. 2011
    ..More recently, LRP1 has been implicated in the catabolism of factor VIII and regulation of its plasma concentrations. The pathophysiology of the role of LRP1 in hemostasis will be summarized in this review...
  12. doi Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Thromb Haemost 104:931-40. 2010
    ..As a result, we have not found definitive evidence supporting a role for product type on inhibitor incidence and inhibitor eradication in haemophilia A patients...
  13. doi Acquired factor V inhibitors: a systematic review
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    J Thromb Thrombolysis 31:449-57. 2011
    ..However, since this preparation is no longer used, in this systematic review we have only focused on non-bovine thrombin-related FV inhibitor cases...
  14. doi Hemostatic abnormalities in endocrine and metabolic disorders
    Massimo Franchini
    Servizio di Immuno ematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria, 43100 Parma, Italy
    Eur J Endocrinol 162:439-51. 2010
    ..Further larger and high-quality studies are needed to provide more definitive information on the effects of endocrine disorders on coagulation and fibrinolysis...
  15. doi Acquired hemophilia in pediatrics: a systematic review
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Pediatr Blood Cancer 55:606-11. 2010
    ..The epidemiology, diagnosis, clinical course, and management of this hemorrhagic disorder in children will be addressed in this systematic review...
  16. doi Errors in transfusion: causes and measures to avoid them
    Massimo Franchini
    Department of Pathology and Laboratory Medicine, Immunohematology and Transfusion Center, University Hospital of Parma, Parma, Italy
    Clin Chem Lab Med 48:1075-7. 2010
    ..In this review, the errors related to blood transfusion are briefly summarized along with new technologies developed for improving blood safety...
  17. ncbi Serum bilirubin levels and cardiovascular disease risk: a Janus Bifrons?
    Massimo Franchini
    Servizio di Immuno ematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Adv Clin Chem 50:47-63. 2010
    ....
  18. doi Disseminated intravascular coagulation in hematologic malignancies
    Massimo Franchini
    Department of Pathology and Laboratory Medicine, Immunohematology and Transfusion Center, University Hospital, Parma, Italy
    Semin Thromb Hemost 36:388-403. 2010
    ..Current approaches and open issues for the management and treatment of these patients are also reviewed...
  19. doi Hyperthyroidism and venous thrombosis: a casual or causal association? A systematic literature review
    Massimo Franchini
    Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Parma, Italy
    Clin Appl Thromb Hemost 17:387-92. 2011
    ....
  20. doi Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review
    Massimo Franchini
    Immunohematology and Transfusion Center, Department of Laboratory and Pathology Medicine, University Hospital of Parma, Via Gramsci 14, Parma, Italy
    Crit Rev Oncol Hematol 81:82-93. 2012
    ..e., plasma-derived versus recombinant FVIII concentrates) does not seem to influence the inhibitor rate in PUPs with severe hemophilia A...
  21. doi The use of recombinant activated FVII in postpartum hemorrhage
    Massimo Franchini
    Department of Pathology and Laboratory Medicine, University Hospital of Parma, Immunohematology and Transfusion Center, Parma, Italy
    Clin Obstet Gynecol 53:219-27. 2010
    ..Finally, on the basis of the evidence from the literature and on own experience, we included some recommendations and an algorithm on the therapeutic role of rFVIIa in the management of PPH...
  22. doi Hepcidin and iron metabolism: from laboratory to clinical implications
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Italy
    Clin Chim Acta 411:1565-9. 2010
    ..The most important advances on the role of hepcidin in normal and abnormal iron metabolism and the main clinical and diagnostic implications are summarized in this review...
  23. doi Recent improvements in the clinical treatment of coagulation factor inhibitors
    Massimo Franchini
    Immunohematology and Transfusion Center, University Hospital of Parma, Parma, Italy
    Semin Thromb Hemost 35:806-13. 2009
    ..The most recent options available for treating patients with acquired hemophilia and congenital hemophilia with inhibitors are addressed in this review...
  24. doi Particulate air pollution and cardiovascular risk: short-term and long-term effects
    Massimo Franchini
    Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Italy
    Semin Thromb Hemost 35:665-70. 2009
    ..The literature data on the short-term and long-term cardiovascular effects of particulate air pollutants are discussed in this review from a clinical and mechanistic point of view...
  25. doi Mild hemophilia A
    M Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    J Thromb Haemost 8:421-32. 2010
    ..Many aspects concerning mild HA remain to be clarified, including the molecular basis, the natural history and the optimal diagnostic and therapeutic strategies. Only large prospective studies will shed light on this condition...
  26. ncbi The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders
    M Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Blood 98:1836-41. 2001
    ..The results confirm the slow progression of HCV infection in HIV-negative hemophiliacs...
  27. doi Effects of secondary prophylaxis started in adolescent and adult haemophiliacs
    A Tagliaferri
    Regional Reference Centre for Inherited Bleeding Disorders, University Hospital, Parma, Italy
    Haemophilia 14:945-51. 2008
    ..With respect to on-demand treatment, higher factor consumption and cost of secondary prophylaxis were balanced by marked clinical benefits and greater well-being in this cohort of adolescent/adult haemophiliacs...
  28. doi The natural history of mild haemophilia: a 30-year single centre experience
    A Tagliaferri
    Regional Reference Centre for Inherited Bleeding Disorders, Department of Medicine, University Hospital of Parma, Parma, Italy
    Haemophilia 18:166-74. 2012
    ..The HTCs should improve patients' knowledge and consideration of their disease and encourage them to maintain regular contact with their haemophilia care provider...
  29. doi LRP1/CD91 is up-regulated in monocytes from patients with haemophilia A: a single-centre analysis
    M Franchini
    Immunohematology and Transfusion Center, Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, Italy
    Haemophilia 19:e126-32. 2013
    ..Further studies are needed to assess the clinical implications of these findings...
  30. doi Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients' analysis
    M Franchini
    Immunohematology and Transfusion Center, City Hospital of Parma, Parma, Italy
    Haemophilia 14:903-12. 2008
    ..Large prospective randomized studies with an adequate follow-up are needed to confirm these preliminary findings...
  31. ncbi Interferon and ribavirin in HIV-negative haemophiliacs with chronic hepatitis C who were nonresponders to a previous interferon treatment
    M Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Haemophilia 8:794-7. 2002
    ..001). Our study shows that IFN and ribavirin combination therapy is effective in HIV-negative chronically HCV-infected haemophiliacs who do not respond to a previous IFN treatment...
  32. ncbi [Menorrhagia and inherited disorders of coagulation]
    M Franchini
    Centro Emofilia, Azienda Ospedaliera, Servizio di Immunoematologia e Trasfusione, Verona, Italy
    Minerva Ginecol 54:453-60. 2002
    ..Since inherited bleeding disorders are frequently associated with menorrhagia, the conclusion is drawn that an underlying congenital bleeding disorder should be ruled out in any woman with menorrhagia...
  33. doi Forum on: the role of recombinant factor VIII in children with severe haemophilia A
    M Franchini
    Immunohaematology and Transfusion Centre, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Parma, Italy
    Haemophilia 15:578-86. 2009
    ..These and other topics concerning rFVIII treatment of haemophilic children were discussed in a meeting held in Rome on 27 February 2008 and are summarized in this report...
  34. doi Is haemophilia B less severe than haemophilia A?
    P M Mannucci
    Scientific Direction, IRCCS Ca Granda Maggiore Policlinico Hospital Foundation, Milan, Italy
    Haemophilia 19:499-502. 2013
    ..In conclusion, these and other data give a hint that HB may be less clinically severe than HA. However, these data are not conclusive, because there are also fewer data in favour of a similar degree of severity of HA and HB...
  35. doi Mortality and causes of death in Italian persons with haemophilia, 1990-2007
    A Tagliaferri
    Regional Reference Centre for Inherited Bleeding Disorders, University Hospital, Parma, Italy
    Haemophilia 16:437-46. 2010
    ..The results of this retrospective study show that in Italian PWH improvements in the quality of treatment and global medical care provided by specialized haemophilia centres resulted in a significantly increased life expectancy...
  36. doi The use of central venous catheters in haemophilia patients
    G Izzi
    Unità Operativa Pediatria e Oncoematologia, Dipartimento Materno Infantile, Parma, Italy
    Haemophilia 16:29-31. 2010
    ..Finally, we describe our personal experience on the use of the external tunnelled catheter Broviac...
  37. ncbi Shortened activated partial thromboplastin time: causes and management
    Giuseppe Lippi
    Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Italy
    Blood Coagul Fibrinolysis 21:459-63. 2010
    ..If the value is systematically confirmed in subsequent samples, please contact the laboratory to help assess the cause'...
  38. doi Prostate-specific antigen, prostate cancer, and disorders of hemostasis
    Giuseppe Lippi
    U O Diagnostica Ematochimica, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospadaliero Universitaria di Parma, Parma, Italy
    Semin Thromb Hemost 35:654-64. 2009
    ....
  39. pmc Evaluation of cardiovascular risk in blood donors: results of the CARDIORISK study in the Parma Transfusion Service
    Paolo Dell'anna
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laoratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Blood Transfus 8:155-8. 2010
    ..In this study, called "Cardiorisk", we evaluated cardiovascular risk in the population of blood donors at the Service of Immunohaematology and Transfusion Medicine in Parma...
  40. ncbi Haemostasis and pregnancy
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Ospedale Policlinico, Piazzale L Scuro, 10, 37134 Verona, Italy
    Thromb Haemost 95:401-13. 2006
    ..Based on an analysis of the literature data, this review presents an overview of the main thrombotic and haemorrhagic disorders complicating pregnancy...
  41. doi Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy
    Giuseppe Lippi
    UO di Diagnostica Ematochimica, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Italy
    Biomark Med 5:63-70. 2011
    ..As such, the aim of this article is to provide an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy in patients undergoing therapy with GPIIb/IIIa antagonists...
  42. pmc Platelet gel in the treatment of cutaneous ulcers: the experience of the Immunohaematology and Transfusion Centre of Parma
    Gino Bernuzzi
    U O Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Via Gramsci 14, Parma, Italy
    Blood Transfus 8:237-47. 2010
    ..Platelet gel is being ever more frequently used to promote healing of cutaneous ulcers. However, the factors that determine the often variable clinical outcome of this procedure are still incompletely understood...
  43. doi The role of anti-core antibody response in the detection of occult hepatitis B virus infection
    Simona Urbani
    Unità Operativa di Immunoematologia e Medicina Trasfusionale, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Clin Chem Lab Med 48:23-9. 2010
    ..The risk of occult hepatitis associated with anti-HBc seropositivity has been demonstrated extensively, and the presence of antibody response to HBc can be considered a sentinel marker of occult HBV infection...
  44. ncbi Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review
    Massimo Franchini
    Immunohematology and Transfusion Center, City Hospital of Verona, Italy
    Blood Coagul Fibrinolysis 18:589-93. 2007
    ..Large randomized trials are needed, however, to confirm the preliminary results and to assess the safety and dosing regimens of this agent in refractory bleeding associated with disseminated intravascular coagulation...
  45. doi Von Willebrand factor: another janus-faced hemostasis protein
    Massimo Franchini
    Immunohematology and Transfusion Centre, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Italy
    Semin Thromb Hemost 34:663-9. 2008
    ..In addition, high plasma levels of VWF have been associated with an increased risk of atherothrombosis. The current article reviews the literature and provides evidence for the two-faced character that VWF therefore represents...
  46. ncbi Venous thromboembolism in chronic liver disease
    Giuseppe Lippi
    UO di Diagnostica Ematochimica, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Semin Thromb Hemost 37:66-76. 2011
    ..The clinical significance of an increased risk of venous thromboembolism in CLD is an important topic for future research, and the initiation of new randomized studies of potential treatments for this complication is needed...
  47. doi Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future
    Giuseppe Lippi
    U O di Diagnostica Ematochimica, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Via Gramsci 14, 43126 Parma, Italy
    J Thromb Thrombolysis 30:459-71. 2010
    ....
  48. doi Inherited and acquired factor V deficiency
    Giuseppe Lippi
    U O di Diagnostica Ematochimica, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Blood Coagul Fibrinolysis 22:160-6. 2011
    ..The aim of the current review is to provide an overview on the physiopathology, diagnostics, and clinical management of both inherited and acquired factor V deficiency...
  49. doi Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy
    S M Siboni
    Department of Medicine and Medical Specialties, Angelo Bianchi Bonomi Hemophlia and Thrombosis Center, University of Milan, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Milan, Italy
    J Thromb Haemost 7:780-6. 2009
    ..There is no information on the health status and quality of life of elderly people with hemophilia born at a time when replacement therapy was hardly available...
  50. ncbi Preoperative autologous blood donation in primary total knee arthroplasty: a single-centre experience on 214 consecutive patients
    M Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
    Vox Sang 90:191-4. 2006
    ....
  51. ncbi Non-ABO red blood cell alloantibodies following allogeneic hematopoietic stem cell transplantation
    M Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
    Bone Marrow Transplant 33:1169-72. 2004
    ....
  52. doi Clinical, laboratory and therapeutic aspects of platelet-type von Willebrand disease
    M Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Int J Lab Hematol 30:91-4. 2008
    ..In this review, the main clinical, laboratory and therapeutic characteristics of PT-VWD are concisely reported...
  53. ncbi Recombinant factor VIIa. An update on its clinical use
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Ospedale Policlinico, Piazzale Ludovico Scuro, 37134 Verona, Italy
    Thromb Haemost 93:1027-35. 2005
    ..Based on a literature search, this review examines the current knowledge on therapy with rFVIIa, from the now well-standardized uses to the newer and less well-characterised clinical applications...
  54. doi Prophylaxis in congenital hemophilia with inhibitors: the role of recombinant activated factor VII
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Semin Thromb Hemost 35:814-9. 2009
    ..The published data on the use of rFVIIa as a prophylactic treatment in hemophilia patients with inhibitors are reviewed in this article...
  55. doi Thyroid dysfunction and hemostasis: an issue still unresolved
    Massimo Franchini
    Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Italy
    Semin Thromb Hemost 35:288-94. 2009
    ..Further trials on larger series of patients are needed to confirm these preliminary findings and to elucidate the pathogenic mechanisms regulating the complex interaction between thyroid disorders and hemostasis...
  56. ncbi Postpartum acquired factor VIII inhibitors
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Am J Hematol 81:768-73. 2006
    ..Based on an analysis of the literature, this review presents the current knowledge on the pathogenesis, diagnosis, epidemiology, natural history, clinical manifestations, and therapeutic management of postpartum acquired hemophilia A...
  57. doi Recombinant activated factor VII: mechanisms of action and current indications
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Semin Thromb Hemost 36:485-92. 2010
    ..The agent's safety profile is also examined, along with recent advances in rFVIIa dosing and storage that may help to improve both clinical outcomes and patient quality of life...
  58. doi Acquired factor VIII inhibitors
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera Universitaria di Parma, Parma, Italy
    Blood 112:250-5. 2008
    ..If confirmed by large controlled studies, these innovative therapies might become a valid option for long-term eradication of factor VIII inhibitors...
  59. ncbi Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Haematologica 88:1279-83. 2003
    ..To evaluate the efficacy and safety of the factor VIII/von Willebrand factor concentrate Haemate-P as replacement therapy in patients with von Willebrand's disease (VWD) undergoing surgical or invasive procedures...
  60. ncbi The use of desmopressin as a hemostatic agent: a concise review
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Am J Hematol 82:731-5. 2007
    ..This review briefly summarizes the current clinical indications on the use of desmopressin as a hemostatic agent...
  61. doi Laboratory, clinical and therapeutic aspects of acquired hemophilia A
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Italy
    Clin Chim Acta 395:14-8. 2008
    ..Moreover, we focus on the most recent advances in the treatment of this disorder, which is primarily aimed to control bleeding episodes and to eradicate the autoantibody production...
  62. doi Extracorporeal immunoadsorption for the treatment of coagulation inhibitors
    Massimo Franchini
    Immunohematology and Transfusion Center, University Hospital of Parma, Parma, Italy
    Semin Thromb Hemost 35:76-80. 2009
    ..However, further randomized clinical trials are needed to better assess the cost-effectiveness of such procedures...
  63. ncbi High prevalence of inherited prothrombotic risk factors in 134 consecutive patients with von Willebrand disease
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
    Am J Hematol 81:465-7. 2006
    ..Three carriers of multiple prothrombotic gene mutations experienced a thrombotic event. Our study suggests that the recent evidence of an association between inherited thrombotic and hemorrhagic disorders also holds true in VWD patients...
  64. ncbi Hemostasis and aging
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Ospedale Policlinico, Piazzale Ludovico Scuro, Azienda Ospedaliera di Verona, 37134 Verona, Italy
    Crit Rev Oncol Hematol 60:144-51. 2006
    ..The complex inter-relationships between inherited and acquired factors influencing the hemostatic system during aging are discussed in this review...
  65. doi Recombinant factor VIII concentrates
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Semin Thromb Hemost 36:493-7. 2010
    ..In this article we review the current knowledge on the commercially available rFVIII concentrates, analyzing their main characteristics. Moreover, results of the literature on their clinical hemostatic efficacy and safety are summarized...
  66. ncbi Biochemistry and physiology of anabolic androgenic steroids doping
    G Lippi
    UO Diagnostica Ematochimica, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Mini Rev Med Chem 11:362-73. 2011
    ..The aim of this article is to review the biochemistry, physiology and the ergogenic effects of AASs...
  67. ncbi Efficacy of desmopressin as surgical prophylaxis in patients with acquired von Willebrand disease undergoing thyroid surgery
    M Franchini
    Servizio di Immunoematologia e Trasfusione, Istituto di Chimica e Microscopia Clinica and Dipartimento di Chirurgia, Verona, Italy
    Haemophilia 8:142-4. 2002
    ..This study highlights the need for coagulation studies in patients with thyroid diseases undergoing thyroid surgery. Subcutaneous desmopressin may be used in these patients in order to prevent a surgically related bleeding risk...
  68. ncbi Unrelated allogeneic bone marrow donation: short- and long-term follow-up of 103 consecutive volunteer donors
    A Gandini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
    Bone Marrow Transplant 28:369-74. 2001
    ..1 months). All donors signed a written informed consent for a further bone marrow collection, if needed. Our findings confirm the short- and long-term safety of allogeneic bone marrow collection in volunteer donors...
  69. ncbi Efficacy of Haemate-P as prophylaxis of recurrent bleeding in a patient with type 2B von Willebrand's disease
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
    Blood Coagul Fibrinolysis 16:571-2. 2005
    ..Prophylaxis with Haemate-P was shown to be safe and effective in this patient, thus enabling completion of radiochemotherapy...
  70. doi Moderate red wine consumption and cardiovascular disease risk: beyond the "French paradox"
    Giuseppe Lippi
    U O Diagnostica Ematochimica, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Semin Thromb Hemost 36:59-70. 2010
    ....
  71. ncbi The role of von Willebrand factor in hemorrhagic and thrombotic disorders
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
    Crit Rev Clin Lab Sci 44:115-49. 2007
    ..The role of VWF in normal and pathological hemostasis is discussed in this review, and important advances in the pathophysiology, diagnosis, and treatment of VWF-associated disorders are also described...
  72. ncbi Rituximab in the treatment of adult acquired hemophilia A: a systematic review
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Ospedale Policlinico, Piazzale Ludovico Scuro, Azienda Ospedaliera di Verona, 37134 Verona, Italy
    Crit Rev Oncol Hematol 63:47-52. 2007
    ..However, large, prospective, randomized trials are needed to confirm these positive preliminary results...
  73. ncbi Advances in the diagnosis and management of von Willebrand disease
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
    Hematology 11:219-25. 2006
    ..In this review, the present knowledge regarding the diagnosis and the management of VWD is briefly analyzed...
  74. ncbi Acquired hemophilia A
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Hematology 11:119-25. 2006
    ..Moreover, new therapeutic strategies (anti-CD20 monoclonal antibody and immune tolerance protocols) are very promising and may further improve the prognosis of acquired hemophilia A...
  75. ncbi Efficacy of desmopressin in preventing hemorrhagic complications in a patient with Marfan syndrome undergoing cardiac surgery
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
    Blood Coagul Fibrinolysis 17:325-6. 2006
    ..In this case report, we describe the successful use of desmopressin as prophylaxis against hemorrhage in a patient with a bleeding tendency associated with Marfan syndrome and a platelet function defect undergoing cardiovascular surgery...
  76. ncbi Von Willebrand factor and thrombosis
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Ospedale Policlinico, Azienda Ospedaliera di Verona, Piazzale L Scuro, 10, 37134, Verona, Italy
    Ann Hematol 85:415-23. 2006
    ..After a description of the structure and physiology of VWF, all these aspects are discussed in the present review...
  77. ncbi The antiphospholipid syndrome: an update
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
    Clin Lab 52:11-7. 2006
    ..The most important advances in the pathophysiology, diagnosis and treatment of this condition are discussed in this review...
  78. ncbi Inherited thrombophilia: an update
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
    Clin Lab 51:357-65. 2005
    ..Finally, we discuss the synergism between genetic and acquired prothrombotic risk factors in some conditions such as pregnancy and cardiovascular diseases...
  79. ncbi Prophylaxis in von Willebrand disease
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Ann Hematol 86:699-704. 2007
    ....
  80. pmc Iron and thrombosis
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Ann Hematol 87:167-73. 2008
    ..The results of the literature on the effect of iron deficiency and overload on vascular health are critically reviewed in this study from a pathogenic and clinical point of view...
  81. pmc Inhibitors in mild/moderate haemophilia A: two case reports and a literature review
    Anna Chiara Giuffrida
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Italy
    Blood Transfus 6:163-8. 2008
  82. pmc Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Italy
    Blood Transfus 6:127-35. 2008
  83. doi The bidirectional relationship of cancer and hemostasis and the potential role of anticoagulant therapy in moderating thrombosis and cancer spread
    Massimo Franchini
    Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Parma, Italy
    Semin Thromb Hemost 35:644-53. 2009
    ..The main biological and clinical evidence on the relationship between cancer and hemostasis are briefly summarized in this review, as is the potential benefits of anticoagulant therapy in this setting...
  84. doi Co-morbidities and quality of life in elderly persons with haemophilia
    Massimo Franchini
    Immunohaematology and Transfusion Centre, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Italy
    Br J Haematol 148:522-33. 2010
    ..This review focuses on co-morbidities in the ageing haemophilia patients, their impact on quality of life and their complex management...
  85. doi The use of desmopressin in congenital factor XI deficiency: a systematic review
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Ann Hematol 88:931-5. 2009
    ..However, these findings need to be supported by further trials on large population of patients...
  86. doi Interpatient phenotypic inconsistency in severe congenital hemophilia: a systematic review of the role of inherited thrombophilia
    Massimo Franchini
    Department of Pathology and Laboratory Medicine, Immunohematology and Transfusion Center, University Hospital of Parma, Italy
    Semin Thromb Hemost 35:307-12. 2009
    ..Further trials on a large population of patients are needed to establish the role of genetic thrombophilia in the phenotypic expression of severe hemophilia...
  87. pmc Adverse reactions in blood and apheresis donors: experience from two Italian transfusion centres
    Isabella Crocco
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
    Blood Transfus 7:35-8. 2009
    ....
  88. doi Thyroid-associated autoimmune coagulation disorders
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    J Thromb Thrombolysis 29:87-91. 2010
    ..Finally, we conclude that the prompt recognition of possible concomitant autoimmune coagulation disorders is important for the correct management of these patients...
  89. ncbi The platelet-function analyzer (PFA-100) for evaluating primary hemostasis
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Hematology 10:177-81. 2005
    ..Given its high sensitivity, speed and simplicity of use, we conclude that the PFA-100 could replace the in vivo bleeding time as a screening test for primary hemostasis in routine clinical practice...
  90. ncbi Thrombotic microangiopathies: an update
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
    Hematology 11:139-46. 2006
    ..In this review, we focus on the epidemiologic and diagnostic criteria as well as on the most recent insights into the pathophysiology and treatment of these two conditions...
  91. ncbi Recent acquisitions in acquired and congenital von Willebrand disorders
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera Policlinico, Piazzale L Scuro, and Istituto di Chimica e Microscopia Clinica, Dipartimento di Scienze Biomediche e Morfologiche, Universita di Verona, Italy
    Clin Chim Acta 377:62-9. 2007
    ..Its deficiency is associated with a bleeding tendency. The progresses in the pathophysiology, diagnosis and management of inherited von Willebrand disease and acquired von Willebrand syndrome will be discussed in this review...
  92. doi Vaccination, squalene and anti-squalene antibodies: facts or fiction?
    Giuseppe Lippi
    U O Diagnostica Ematochimica, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Eur J Intern Med 21:70-3. 2010
    ..This review summarizes the current scientific evidence about the relationship between squalene, anti-squalene antibodies and vaccination...
  93. ncbi Iron overload and hematologic malignancies
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, 37134 Verona, Italy
    Hematol J 5:381-3. 2004
    ..In this review, we briefly report the present knowledge regarding the association between iron overload and hematologic malignancies...